戻る 戻る
細胞番号 : 細胞名
RCB0035 : WEHI-3  update : 2022/12/21
細胞特性(Comment:英)Mouse cell line derived from leukemia. Secretes cytokines for hematopoietic cells.
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Kanazawa, Satoshi
寄託日 1987
別名 W3(H)
動物種 mouse < Mammals
動物系統名 BALB/c
採取組織 blood
病名 leukemia
細胞分類 other
入手歴 Hirosima Univ.- Yanagihara
細胞寿命 infinite
細胞形態 lymphocyte-like
Cellosaurus(Expasy) CVCL_3622
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Suspension cells
培地 RPMI1640 + 10% FBS
抗生物質 Free
継代方法 dilution
継代密度 1 : 10 split
継代・培地交換頻度 Subculture : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
マウス系統検査 OK
アイソザイム検査 LD, NP
文献情報 Reference(英) 13件
Reference(日) 1件
利用者成果(英) 20件
利用者成果(日) 0件

922  Almeida JL, Dakic A, Kindig K, Kone M, Letham DLD, Langdon S, Peat R, Holding-Pillai J, Hall EM, Ladd M, Shaffer MD, Berg H, Li J, Wigger G, Lund S, Steffen CR, Fransway BB, Geraghty B, Natoli M, Bauer B, Gollin SM, Lewis DW, Reid Y.  Interlaboratory study to validate a STR profiling method for intraspecies identification of mouse cell lines  PLoS One  2019  14(6):e0218412  PubMed ID: 31220119   DOI: 10.1371/journal.pone.0218412
143  Walker EB, Lanier LL, Warner NL.  Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line  J Exp Med  1982  155(2):629-34  PubMed ID: 6173461   DOI: 10.1084/jem.155.2.629
92  Walker EB, Lanier LL, Warner NL.  Characterization and functional properties of tumor cell lines in accessory cell replacement assays  J Immunol  1982  128(2):852-9  PubMed ID: 7033383  
5287  McKean DJ, Infante AJ, Nilson A, Kimoto M, Fathman CG, Walker E, Warner N.  Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells.  J Exp Med  1981  154(5):1419-31  PubMed ID: 6170720   DOI: 10.1084/jem.154.5.1419
17  Baca OG, Akporiaye ET, Aragon AS, Martinez IL, Robles MV, Warner NL.  Fate of phase I and phase II Coxiella burnetii in several macrophage-like tumor cell lines  Infect Immun  1981  33(1):258-66  PubMed ID: 7263063   DOI: 10.1128/iai.33.1.258-266.1981
980  Metcalf D  Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin.  Int J Cancer  1980  25:225-33  PubMed ID: 6967053   DOI: 10.1002/ijc.2910250210
1294  Ralph P, Nakoinz I  Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture.  Cancer Res  1977  37:546-50  PubMed ID: 318922  
716  Ralph P, Nakoinz I  Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS.  J Immunol  1977  119:950-54  PubMed ID: 894031  
1141  Ralph P, Moore, M A, Nilsson K  Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.  J Exp Med  1976  143:1528-33  PubMed ID: 1083890   DOI: 10.1084/jem.143.6.1528
31  Röllinghoff M, Warner NL.  Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells  Proc Soc Exp Biol Med  1973  144(3):813-8  PubMed ID: 4543620   DOI: 10.3181/00379727-144-37688
126  Rouse BT, Röllinghoff M, Warner NL.  Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response  Eur J Immunol  1973  3(4):218-24  PubMed ID: 4541468   DOI: 10.1002/eji.1830030408
5289  Metcalf D, Moore MA, Warner NL.  Colony formation in vitro by myelomonocytic leukemic cells.  J Natl Cancer Inst  1969  43(4):983-1001  PubMed ID: 5259326  
84  Warner NL, Moore MA, Metcalf D.  A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content  J Natl Cancer Inst  1969  43(4):963-8  PubMed ID: 5259325  

1220  冨田幹夫  バイオテクノロジ-素材としての培養細胞 細胞分化(I)  蛋白質 核酸 酵素  1988  33:05:00   

16770  Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.  Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation  J Hematol Oncol  2022  15(1):79  PubMed ID: 35690785   DOI: 10.1186/s13045-022-01299-z
11561  Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T.  An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors.  J Cosmet Dermatol  2020  19(2):477-484  PubMed ID: 31099492   DOI: 10.1111/jocd.12997
11622  Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.  J Thorac Oncol  2019  14(10):1753-1765  PubMed ID: 31279006   DOI: 10.1016/j.jtho.2019.06.023
17202  Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S.  Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia  Haematologica  2019  104(10):e447-e450  PubMed ID: 30890597   DOI: 10.3324/haematol.2018.210856
11331  Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.  Lung Cancer  2018    PubMed ID: 30527179   DOI: 10.1016/j.lungcan.2018.10.026
4860  Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.  Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.  Exp Hematol  2016  44(3):177-88.e5  PubMed ID: 26703895   DOI: 10.1016/j.exphem.2015.11.009
14149  Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, Fujii S.  Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells  Cancer Res  2016  76(13):3756-66  PubMed ID: 27371739   DOI: 10.1158/0008-5472.CAN-15-3219
15120  Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.  EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs  Clin Cancer Res  2015  21(23):5305-13  PubMed ID: 26206867   DOI: 10.1158/1078-0432.CCR-15-1046
8857  Tao Y, Nomura M, Kitabatake N, Tani F.  Mouse CD40-transfected cell lines cannot exhibit the binding and RANTES-stimulating activity of exogenous heat shock protein 70.  Mol. Immunol.  2007  44:1262-73  PubMed ID: 16930707   DOI: 10.1016/j.molimm.2006.06.002
2559  Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M  A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells.  J Biol Chem  2001  276:11031-40  PubMed ID: 11134040   DOI: 10.1074/jbc.M003535200
2473  Tanaka I, Ishihara H  Enhanced expression of the early retrotransposon in C3H mouse-derived myeloid leukemia cells.  Virology  2001  280:107-14  PubMed ID: 11162824   DOI: 10.1006/viro.2000.0732
4871  Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M.  Cell-free entry of human T-cell leukemia virus type 1 to mouse cells.  Jpn J Cancer Res  2001  92(4):410-6  PubMed ID: 11346463   DOI: 10.1111/j.1349-7006.2001.tb01110.x
16915  Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K.  PAL31, a nuclear protein required for progression to the S phase  Biochem Biophys Res Commun   2001  280(4):1048-54  PubMed ID: 11162633   DOI: 10.1006/bbrc.2000.4244
2951  Yokota S, Kayano T, Ohta T, Kurimoto M, Yanagi H, Yura T, Kubota H  Proteasome-dependent degradation of cytosolic chaperonin CCT  Biochemical and biophysical research communications  2000  279:712-717  PubMed ID: 11118350   DOI: 10.1006/bbrc.2000.4011
2380  Yokota S, Yanagi H, Yura T, Kubota H  Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase.  J Biol Chem  1999  274:37070-8  PubMed ID: 10601265   DOI: 10.1074/jbc.274.52.37070
2215  Saneyoshi K, Nohara O, Imai T, Shiraishi F, Moriyama H, Fujimaki H  IL-4 and IL-6 production of bone marrow-derived mast cells is enhanced by treatment with environmental pollutants.  Int Arch Allergy Immunol  1997  114:237-45  PubMed ID: 9363904   DOI: 10.1159/000237674
2216  Fujimaki H, Nohara O, Katayama N, Abe T, Nohara K  Ganglioside GM3 inhibits interleukin-3-dependent bone marrow-derived mast cell proliferation.  Int Arch Allergy Immunol  1995  107:527-32  PubMed ID: 7620368   DOI: 10.1159/000237095
5411  Nakamura M, Sakanaka C, Aoki Y, Ogasawara H, Tsuji T, Kodama H, Matsumoto T, Shimizu T, Noma M.  Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors.  J Biol Chem  1995  270(50):30102-10  PubMed ID: 8530415   DOI: 10.1074/jbc.270.50.30102
1730  Katayama, N., Honda, Y. and Fujimaki, H.  Growth and Functional Modifications in Formaldehyde-Treated Mouse Bone Marrow-Derived Mast Cells  Toxicol in Vitro  1992  6:239-243  PubMed ID: 20732119   DOI: 10.1016/0887-2333(92)90037-r
1731  Fujimaki H, Kawagoe A, Bissonnette E, Befus D  Mast cell response to formaldehyde. 1. Modulation of mediator release.  Int Arch Allergy Immunol  1992  98:324-31  PubMed ID: 1384864   DOI: 10.1159/000236206


戻る 戻る 理研トップページへ